DALLAS, June 30, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Insmed Inc. (Nasdaq:INSM). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/INSM
The MACD for INSM currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of zero, which implies that the underlying moving averages are trending lower.
Insmed Inc. (INSM) is a biopharmaceutical company specializing in recombinant protein drug development. Until 2009, the Company was engaged in pursuing a dual path strategy involving entry into the follow-on biologics (FOB) arena (also known as biosimilars and biogenerics) and advancing its protein platform, centered on its IPLEX product, into markets with unmet needs. IPLEX is in various stages of development for a number of serious medical conditions, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, and Retinopathy of Prematurity (ROP). On March 31, 2009, the Company completed the sale of its FOB platform to Merck & Co. Inc. (Merck).
Message Board Search for INSM: http://www.boardcentral.com/boards/INSM
In the report, the analyst notes:
"Total revenues for the first quarter ended March 31, 2010, were $1.9 million, as compared to $2.4 million for the corresponding period in 2009. The $441,000 decline in revenue was due to the receipt of $272,000 in grant revenue for the Myotonic Muscular Dystrophy (MMD) trial in the first quarter of 2009, $143,000 in lower cost recovery in the most recent quarter from our Expanded Access Program (EAP) for IPLEX(TM) in the treatment of Amyotrophic Lateral Sclerosis (ALS) in Italy and $26,000 in lower income from a long standing TGF-beta royalty which expired in the current quarter.
"INSM recently announced that on June 18, 2010, it received a NASDAQ Staff Deficiency Letter from The NASDAQ Stock Market. The NASDAQ Letter states that for the last 30 consecutive business days, the closing bid price per share for the Company's common stock has been below the $1.00 minimum per share requirement for continued inclusion under NASDAQ Marketplace Rule 5550(a)(2)."
To read the entire report visit: http://www.microstockprofit.com/lp/INSM
See what investors are saying about INSM at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.